Recruiting
Phase 2

Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

Sponsor:

Hoffmann-La Roche

Code:

NCT05630066

Conditions

Angelman Syndrome

Eligibility Criteria

Sex: All

Age: 5 - 17

Healthy Volunteers: Not accepted

Interventions

60 mg QD Alogabat

40 mg QD Alogabat

7 mg QD Alogabat

Part 2 Adult Alogabat High Dose (aged 15-17)

Alogabat

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information